<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37596838</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>229</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Modeling Poliovirus Transmission and Responses in New York State.</ArticleTitle><Pagination><StartPage>1097</StartPage><EndPage>1106</EndPage><MedlinePgn>1097-1106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiad355</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In July 2022, New York State (NYS) reported a case of paralytic polio in an unvaccinated young adult, and subsequent wastewater surveillance confirmed sustained local transmission of type 2 vaccine-derived poliovirus (VDPV2) in NYS with genetic linkage to the paralyzed patient.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We adapted an established poliovirus transmission and oral poliovirus vaccine evolution model to characterize dynamics of poliovirus transmission in NYS, including consideration of the immunization activities performed as part of the declared state of emergency.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Despite sustained transmission of imported VDPV2 in NYS involving potentially thousands of individuals (depending on seasonality, population structure, and mixing assumptions) in 2022, the expected number of additional paralytic cases in years 2023 and beyond is small (less than 0.5). However, continued transmission and/or reintroduction of poliovirus into NYS and other populations remains a possible risk in communities that do not achieve and maintain high immunization coverage.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In countries such as the United States that use only inactivated poliovirus vaccine, even with high average immunization coverage, imported polioviruses may circulate and pose a small but nonzero risk of causing paralysis in nonimmune individuals.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routh</LastName><ForeName>Janell A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>I Ravi</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Office of Public Health, New York State Department of Health, Albany, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Eli S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Office of Public Health, New York State Department of Health, Albany, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, State University of New York at Albany, Albany, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucker</LastName><ForeName>Jane R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>New York City Department of Health and Mental Hygiene, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langdon-Embry</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York City Department of Health and Mental Hygiene, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugerman</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4900-9455</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915-02-00</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079686" MajorTopicYN="N">Wastewater-Based Epidemiological Monitoring</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">New York</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">modeling</Keyword><Keyword MajorTopicYN="N">outbreak</Keyword><Keyword MajorTopicYN="N">polio</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors: no reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>19</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37596838</ArticleId><ArticleId IdType="mid">NIHMS2009844</ArticleId><ArticleId IdType="pmc">PMC11284859</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad355</ArticleId><ArticleId IdType="pii">7246204</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Badizadegan K, Kalkowska DA, Thompson KM. Polio by the numbers: a global perspective. J Infect Dis 2022; 226: 1309â€“18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556648</ArticleId><ArticleId IdType="pubmed">35415741</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Editorial Board. Polio eradication: falling at the final hurdle? Lancet 2022; 400:1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">36183713</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine 2015; 33:1568â€“77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2000; 49:1â€“22.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006; 26:1423â€“40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184390</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391â€“7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19090774</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. New Eng J Med 2011; 364:2316â€“23.</Citation><ArticleIdList><ArticleId IdType="pubmed">21675890</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimble R, Atkins J, Quigg TC, et al. Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndromeâ€”Texas, 2013. MMWR Morb Mortal Wkly Rep 2014; 63: 721â€“4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779436</ArticleId><ArticleId IdType="pubmed">25144542</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewaterâ€”New York, Juneâ€“August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1065â€“8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>New York State Department of Health. Polio vaccination rates by county. https://health.ny.gov/diseases/communicable/polio/county_vaccination_rates.htm.
Accessed
3 January 2023.</Citation></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, et al. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio caseâ€”New York, March 9â€“October 11, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1418â€“24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman NS, Bar-Or I, Sofer D, et al. Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill 2022; 27:2200694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9479469</ArticleId><ArticleId IdType="pubmed">36111556</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapsa D, Wilton T, Zealand A, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet 2022; 400:1531â€“8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization. Epidemiological update detection of poliovirus in wastewater: Considerations for the Region of the Americas 30 December 2022. https://www.paho.org/en/documents/epidemiological-update-detection-poliovirus-wastewater.
Accessed
31 December 2022.</Citation></Reference><Reference><Citation>World Health Organization-Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus, Geneva, Switzerland: WHO; 2023. https://polioeradication.org/this-week/circulating-vaccine-derived-poliovirus/.
Accessed
1 May 2023.</Citation></Reference><Reference><Citation>Thompson KM, Wallace GS, Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012; 127: 23â€“37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisjes KH, Duintjer Tebbens RJ, Wallace GS, et al. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. J Infect Dis 2014; 210(Suppl 1):S424â€“33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944487</ArticleId><ArticleId IdType="pubmed">25316864</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Logan GE. Characterization of heterogeneity in childhood immunization coverage in Central Florida using immunization registry data. Risk Anal 2016; 36:1418â€“26.</Citation><ArticleIdList><ArticleId IdType="pubmed">26033542</ArticleId></ArticleIdList></Reference><Reference><Citation>New York State Department of Health and Mental Hygiene. Polio vaccination coverage with three doses, by New York City modified zip code tabulation areas. https://www.nyc.gov/assets/doh/downloads/pdf/cd/polio-vaccination-coverage-by-zip.pdf.
Accessed
3 January 2023.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013; 33:703â€“49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Global transmission of live polioviruses: updated dynamic modeling of the polio endgame. Risk Anal 2021; 41:248â€“65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33:680â€“702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis 2015; 15:376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574692</ArticleId><ArticleId IdType="pubmed">26382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect 2019; 147:e295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33:647â€“63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveillance 2013; 18:20586.</Citation><ArticleIdList><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis 2015; 211:1800â€“12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Qi Q, Zhang Y, et al. Analysis of a Sabin-strain inactivated poliovirus vaccine response to a circulating type 2 vaccine-derived poliovirus event in Sichuan Province, China 2019â€“2021. JAMA Netw Open 2023; 6: e2249710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856606</ArticleId><ArticleId IdType="pubmed">36602797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoev A, Macklin GR, Zhang Y, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob Health 2022; 10: e1807â€“e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>Seither R, Calhoun K, Yusuf OB, et al. Vaccination coverage with selected vaccines and exemption rates among children in kindergartenâ€”United States, 2021â€“22 school year. MMWR Morb Mortal Wkly Rep 2023; 72:26â€“32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9869733</ArticleId><ArticleId IdType="pubmed">36634005</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Badizadegan K. A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. Risk Anal 2021; 41: 376â€“86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983986</ArticleId><ArticleId IdType="pubmed">33084153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill DT, Larsen DA. Using geographic information systems to link population estimates to wastewater surveillance data in New York State, USA. PLOS Glob Public Health 2023; 3:e0001062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10021809</ArticleId><ArticleId IdType="pubmed">36962986</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>